Filing Flows › Novartis AG (NVS) › Capital expenditures
Novartis AG (NVS) capital expenditures by quarter
Novartis AG's capital expenditures were $392M in Q3 2026 (third quarter 2026), +22% from Q2 2026. Over the last 6 quarters it ranged from $321M (Q2 2026) to $609M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $392M | +22% | +11% |
| Q2 2026 | $321M | -7% | -3% |
| Q1 2026 | $346M | -43% | — |
| Q4 2025 | $609M | +72% | — |
| Q3 2025 | $354M | +7% | — |
| Q2 2025 | $331M | — | — |
Q3 2026 at a glance
Novartis AG, Q3 2026: revenue $14.5B (+4% year over year), operating margin 12.7%, net earnings $1.2B, operating cash flow $5.5B. The chart follows the revenue to costs, profit and cash.
Questions
What is Novartis AG's capital expenditures?
Novartis AG's capital expenditures were $392M in Q3 2026 (third quarter 2026), +22% from Q2 2026.
How has Novartis AG's capital expenditures changed?
Over the last 6 quarters it ranged from $321M (Q2 2026) to $609M (Q4 2025).